Preparation and characterization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles
-
Add time:07/21/2019 Source:sciencedirect.com
Citral-loaded solid lipid nanoparticles (citral-SLNs) were prepared via a high-pressure homogenization method, using glyceryl monostearate (GMS) as the solid lipid and a mixture of Tween 80 (T-80) and Span 80 (S-80) at a weight ratio of 1:1 as the surfactant. The microstructure and properties of the citral-SLNs were characterized by dynamic light scattering (DLS), scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD) and thermal gravimetric analysis (TGA). The chemical stability of citral in the citral-SLNs was analyzed by solid-phase microextraction gas chromatography (SPME-GC). The GC results showed that 67.0% of the citral remained in the citral-SLN suspensions after 12 days, while only 8.22% remained in the control. Therefore, the encapsulation of citral in the solid lipid can enhance its stability in acidic surroundings.
We also recommend Trading Suppliers and Manufacturers of Citral (cas 5392-40-5). Pls Click Website Link as below: cas 5392-40-5 suppliers
Prev:In vitro DNA binding studies of therapeutic and prophylactic drug Citral (cas 5392-40-5)
Next:Anti-hyperalgesic and anti-inflammatory effects of Citral (cas 5392-40-5) with β-cyclodextrin and hydroxypropyl-β-cyclodextrin inclusion complexes in animal models) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Vasorelaxant effect of the Lippia alba essential oil and its major constituent, Citral (cas 5392-40-5), on the contractility of isolated rat aorta07/22/2019
- Anti-hyperalgesic and anti-inflammatory effects of Citral (cas 5392-40-5) with β-cyclodextrin and hydroxypropyl-β-cyclodextrin inclusion complexes in animal models07/20/2019
- In vitro DNA binding studies of therapeutic and prophylactic drug Citral (cas 5392-40-5)07/19/2019
- Anti-inflammatory and anti-cancer activity of Citral (cas 5392-40-5): Optimization of Citral (cas 5392-40-5)-loaded solid lipid nanoparticles (SLN) using experimental factorial design and LUMiSizer®07/18/2019
- Physiological response of Saccharomyces cerevisiae to Citral (cas 5392-40-5) combined with thermal treatment07/17/2019
- Antifungal activity and mechanism of Citral (cas 5392-40-5), limonene and eugenol against Zygosaccharomyces rouxii07/16/2019
- Effect of drying and interfacial membrane composition on the antimicrobial activity of emulsified Citral (cas 5392-40-5)07/15/2019